Email Alert RSS
Volume 14 Issue 4
Jul.  2023
Turn off MathJax
Article Contents
Abstract
References
Related Articles
CHEN Danni, WANG Shiling, LU Hong, ZHENG Ya, WANG Yuping, REN Qian. Relationship and Potential Mechanism Between Helicobacter Pylori Infection and Non-alcoholic Fatty Liver Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 833-838. DOI: 10.12290/xhyxzz.2022-0710
Citation: CHEN Danni, WANG Shiling, LU Hong, ZHENG Ya, WANG Yuping, REN Qian. Relationship and Potential Mechanism Between Helicobacter Pylori Infection and Non-alcoholic Fatty Liver Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 833-838. DOI: 10.12290/xhyxzz.2022-0710
shu

Relationship and Potential Mechanism Between Helicobacter Pylori Infection and Non-alcoholic Fatty Liver Disease

  • 1.

    The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China

  • 2.

    Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou 730000, China

  • 3.

    Digestive Endoscope Center, The First Hospital of Lanzhou University, Lanzhou 730000, China

  • 4.

    Gansu Key Laboratory of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou 730000, China

Funds: 

Natural Science Foundation of Gansu Province 21JR7RA381

Health Industry Research Project of Gansu Province GSWSKY2020-07

Fundamental Research Funds for the Central Universities lzujbky-2021-ct17

Hospital Foundation of Lanzhou University First Hospital ldyyyn2019-74

More Information
  • Corresponding author:

    REN Qian, E-mail: ldyy_renqian@lzu.edu.cn

  • Received Date: December 10, 2022
  • Accepted Date: February 08, 2023
  • Issue Publish Date: July 29, 2023
    Graphical Abstract
    • Abstract
  • Since people's lifestyles have changed, non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent liver condition globally. It can progress to cirrhosis and hepatocellular carcinoma (HCC), both of which pose major risks to people's health. Currently, the treatment of NAFLD is still based on lifestyle modification, glycemic and lipid control, and other risk factors, and there are no effective therapeutic drugs. Therefore, it is important to study the pathogenesis of NAFLD. Recent studies have shown that Helicobacter pylori (HP) infection is associated with the development of NAFLD, and HP infection may contribute to the development of NAFLD by inducing insulin resistance, altering the lipid profile, promoting oxidative stress, changing intestinal permeability, and regulating gene expression. Therefore, this paper reviews the correlation between HP infection and NAFLD and the potential pathogenesis of NAFLD due to HP infection, with the aim of providing new ideas for the diagnosis and treatment of NAFLD.
    • FullText(HTML)
    • References (67)
  • [1]
    Younossi ZM, Marchesini G, Pinto-Cortez H, et al. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation[J]. Transplantation, 2019, 103: 22-27. DOI: 10.1097/TP.0000000000002484
    [2]
    Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J]. Metabolism, 2016, 65: 1038-1048. DOI: 10.1016/j.metabol.2015.12.012
    [3]
    Negi CK, Babica P, Bajard L, et al. Insights into the molecular targets and emerging pharmacotherapeutic interven-tions for nonalcoholic fatty liver disease[J]. Metabolism, 2022, 126: 154925. DOI: 10.1016/j.metabol.2021.154925
    [4]
    Santos MLC, De Brito BB, Da Silva FAF, et al. Helicobacter pylori infection: Beyond gastric manifestations[J]. World J Gastroenterol, 2020, 26: 4076-4093. DOI: 10.3748/wjg.v26.i28.4076
    [5]
    Cindoruk M, Cirak MY, Unal S, et al. Identification of Helicobacter species by 16S rDNA PCR and sequence analysis in human liver samples from patients with various etiologies of benign liver diseases[J]. Eur J Gastroenterol Hepatol, 2008, 20: 33-36. DOI: 10.1097/MEG.0b013e3282efa4f2
    [6]
    He C, Cheng D, Wang H, et al. Helicobacter pylori infection aggravates diet-induced nonalcoholic fatty liver in mice[J]. Clin Res Hepatol Gastroenterol, 2018, 42: 360-367. DOI: 10.1016/j.clinre.2017.12.008
    [7]
    Abo-Amer YE, Sabal A, Ahmed R, et al. Relationship Between Helicobacter pylori Infection and Nonalcoholic Fatty Liver Disease (NAFLD) in a Developing Country: A Cross-Sectional Study[J]. Diabetes Metab Syndr Obes, 2020, 13: 619-625. DOI: 10.2147/DMSO.S237866
    [8]
    Yu YY, Tong YL, Wu LY, et al. Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial[J]. Sci Rep, 2022, 12: 19530. DOI: 10.1038/s41598-022-23746-0
    [9]
    Chen C, Zhang C, Wang X, et al. Helicobacter pylori infection may increase the severity of nonalcoholic fatty liver disease via promoting liver function damage, glycometabolism, lipid metabolism, inflammatory reaction and metabolic syndrome[J]. Eur J Gastroenterol Hepatol, 2020, 32: 857-866. DOI: 10.1097/MEG.0000000000001601
    [10]
    Wei L, Ding HG. Relationship between Helicobacter pylori infection and nonalcoholic fatty liver disease: What should we expect from a meta-analysis?[J]. Medicine (Baltimore), 2021, 100: e26706. DOI: 10.1097/MD.0000000000026706
    [11]
    Mantovani A, Turino T, Altomari A, et al. Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis[J]. Metabolism, 2019, 96: 56-65. DOI: 10.1016/j.metabol.2019.04.012
    [12]
    Heydari K, Yousefi M, Alizadeh-Navaei R, et al. Helicobacter pylori Infection and Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis[J]. Turk J Gastroenterol, 2022, 33: 171-181. DOI: 10.5152/tjg.2022.21467
    [13]
    Ma Z, Chu X, Yan X, et al. Association between Helicobacter pylori infection and non-alcoholic fatty liver disease for Asian and non-Asian population: A systematic review and meta-analysis[J]. Front Public Health, 2022, 10: 1062942. DOI: 10.3389/fpubh.2022.1062942
    [14]
    Liu R, Liu Q, He Y, et al. Association between Helico-bacter pylori infection and nonalcoholic fatty liver: A meta-analysis[J]. Medicine (Baltimore), 2019, 98: e17781. DOI: 10.1097/MD.0000000000017781
    [15]
    Liu Y, Xu H, Zhao Z, et al. No evidence for a causal link between Helicobacter pylori infection and nonalcoholic fatty liver disease: A bidirectional Mendelian randomization study[J]. Front Microbiol, 2022, 13: 1018322. DOI: 10.3389/fmicb.2022.1018322
    [16]
    Okushin K, Takahashi Y, Yamamichi N, et al. Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan[J]. BMC Gastroenterol, 2015, 15: 25. DOI: 10.1186/s12876-015-0247-9
    [17]
    Baeg MK, Yoon SK, Ko SH, et al. Helicobacter pylori infection is not associated with nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2016, 22: 2592-2600. DOI: 10.3748/wjg.v22.i8.2592
    [18]
    Wang W, Fan M, Gong R, et al. Helicobacter pylori infection is not an independent risk factor of non-alcoholic fatty liver disease in China[J]. BMC Gastroenterol, 2022, 22: 81. DOI: 10.1186/s12876-022-02148-6
    [19]
    Kazemifar AM, Shafikhani AA, Hajinoormohammadi E, et al. Investigating effect of Helicobacter pylori treatment on improvement of non-alcoholic fatty liver parameters: a randomized trial[J]. Egyptian Liver J, 2019, 9: 2. DOI: 10.1186/s43066-019-0001-z
    [20]
    Sohouli MH, Sayyari AA, Lari A, et al. Association of dietary insulinaemic potential and odds of non-alcoholic fatty liver disease among adults: A case-control study[J]. J Hum Nutr Diet, 2021, 34: 901-909. DOI: 10.1111/jhn.12865
    [21]
    Smith GI, Shankaran M, Yoshino M, et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease[J]. J Clin Invest, 2020, 130: 1453-1460. DOI: 10.1172/JCI134165
    [22]
    Polyzos SA, Kountouras J, Zavos C, et al. The association between Helicobacter pylori infection and insulin resistance: a systematic review[J]. Helicobacter, 2011, 16: 79-88. DOI: 10.1111/j.1523-5378.2011.00822.x
    [23]
    Vafaeimanesh J, Bagherzadeh M, Heidari A, et al. Diabetic patients infected with Helicobacter pylori have a higher Insulin Resistance Degree[J]. Caspian J Intern Med, 2014, 5: 137-142.
    [24]
    Liou JM, Chen CC, Chang CM, et al. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial[J]. Lancet Infect Dis, 2019, 19: 1109-1120. DOI: 10.1016/S1473-3099(19)30272-5
    [25]
    Aydemir S, Bayraktaroglu T, Sert M, et al. The effect of Helicobacter pylori on insulin resistance[J]. Dig Dis Sci, 2005, 50: 2090-2093. DOI: 10.1007/s10620-005-3012-z
    [26]
    Azami M, Baradaran HR, Dehghanbanadaki H, et al. Association of Helicobacter pylori infection with the risk of metabolic syndrome and insulin resistance: an updated systematic review and meta-analysis[J]. Diabetol Metab Syndr, 2021, 13: 145. DOI: 10.1186/s13098-021-00765-x
    [27]
    郑凤, 张水英, 孙茂原, 等. 慢性胃炎患者幽门螺旋杆菌感染与IL-6、IL-8和TNF-α的表达研究[J]. 中国初级卫生保健, 2021, 35: 90-91, 94 https://www.cnki.com.cn/Article/CJFDTOTAL-ZGCW202107028.htm
    [28]
    Kumar V, Kiran S, Kumar S, et al. Extracellular vesicles in obesity and its associated inflammation[J]. Int Rev Immunol, 2022, 41: 30-44. DOI: 10.1080/08830185.2021.1964497
    [29]
    Khan RS, Bril F, Cusi K, et al. Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease[J]. Hepatology, 2019, 70: 711-724. DOI: 10.1002/hep.30429
    [30]
    Kakino S, Ohki T, Nakayama H, et al. Pivotal Role of TNF-α in the Development and Progression of Nonalcoholic Fatty Liver Disease in a Murine Model[J]. Horm Metab Res, 2018, 50: 80-87. DOI: 10.1055/s-0043-118666
    [31]
    Leto D, Saltiel AR. Regulation of glucose transport by insulin: traffic control of GLUT4[J]. Nat Rev Mol Cell Biol, 2012, 13: 383-396. DOI: 10.1038/nrm3351
    [32]
    Bian F, Yang XY, Xu G, et al. CRP-Induced NLRP3 Inflammasome Activation Increases LDL Transcytosis Across Endothelial Cells[J]. Front Pharmacol, 2019, 10: 40. DOI: 10.3389/fphar.2019.00040
    [33]
    Fernández-Real JM, Broch M, Vendrell J, et al. Interleukin-6 gene polymorphism and insulin sensitivity[J]. Diabetes, 2000, 49: 517-520. DOI: 10.2337/diabetes.49.3.517
    [34]
    Duan Y, Pan X, Luo J, et al. Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease[J]. Front Immunol, 2022, 13: 880298. DOI: 10.3389/fimmu.2022.880298
    [35]
    Abdel-Razik A, Mousa N, Shabana W, et al. Helicobacter pylori and non-alcoholic fatty liver disease: A new enigma?[J]. Helicobacter, 2018, 23: e12537.
    [36]
    Kim YS, Lee SH, Park SG, et al. Low levels of total and high-molecular-weight adiponectin may predict non-alcoholic fatty liver in Korean adults[J]. Metabolism, 2020, 103: 154026. DOI: 10.1016/j.metabol.2019.154026
    [37]
    Mantovani A, Zusi C, Csermely A, et al. Association between lower plasma adiponectin levels and higher liver stiffness in type 2 diabetic individuals with nonalcoholic fatty liver disease: an observational cross-sectional study[J]. Hormones (Athens), 2022, 21: 477-486. DOI: 10.1007/s42000-022-00387-6
    [38]
    Gastaldelli A, Sabatini S, Carli F, et al. PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH[J]. Liver Int, 2021, 41: 2659-2670. DOI: 10.1111/liv.15005
    [39]
    Hemmasi G, Zamani F, Khonsari M, et al. Association between Helicobacter pylori and Serum Leptin in Iranian Dyspeptic Patients[J]. Middle East J Dig Dis, 2013, 5: 158-162.
    [40]
    Pérez-Pérez A, Sánchez-Jiménez F, Vilariño-García T, et al. Role of Leptin in Inflammation and Vice Versa[J]. Int J Mol Sci, 2020, 21: 5887. DOI: 10.3390/ijms21165887
    [41]
    Shimamoto T, Yamamichi N, Gondo K, et al. The association of Helicobacter pylori infection with serum lipid profiles: An evaluation based on a combination of meta-analysis and a propensity score-based observational approach[J]. PLoS One, 2020, 15: e0234433. DOI: 10.1371/journal.pone.0234433
    [42]
    Park Y, Kim TJ, Lee H, et al. Eradication of Helicobacter pylori infection decreases risk for dyslipidemia: A cohort study[J]. Helicobacter, 2021, 26: e12783.
    [43]
    Eshraghian A, Nikeghbalian S, Shamsaeefar A, et al. Hepatic steatosis and liver fat contents in liver transplant recipients are associated with serum adipokines and insulin resistance[J]. Sci Rep, 2020, 10: 12701. DOI: 10.1038/s41598-020-69571-1
    [44]
    Stefan N, Häring HU. The role of hepatokines in metabolism[J]. Nat Rev Endocrinol, 2013, 9: 144-152. DOI: 10.1038/nrendo.2012.258
    [45]
    Hennige AM, Staiger H, Wicke C, et al. Fetuin-A induces cytokine expression and suppresses adiponectin production[J]. PLoS One, 2008, 3: e1765. DOI: 10.1371/journal.pone.0001765
    [46]
    Shim YS, Kang MJ, Oh YJ, et al. Fetuin-A as an Alternative Marker for Insulin Resistance and Cardiovascular Risk in Prepubertal Children[J]. J Atheroscler Thromb, 2017, 24: 1031-1038. DOI: 10.5551/jat.38323
    [47]
    Jirak P, Stechemesser L, Moré E, et al. Clinical implications of fetuin-A[J]. Adv Clin Chem, 2019, 89: 79-130.
    [48]
    Pal D, Dasgupta S, Kundu R, et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance[J]. Nat Med, 2012, 18: 1279-1285. DOI: 10.1038/nm.2851
    [49]
    Filardi T, Panimolle F, Tiberti C, et al. Circulating levels of fetuin-A are associated with moderate-severe hepatic steatosis in young adults[J]. J Endocrinol Invest, 2021, 44: 105-110. DOI: 10.1007/s40618-020-01274-w
    [50]
    Chen LW, Kuo SF, Chen CH, et al. A community-based study on the association between Helicobacter pylori Infection and obesity[J]. Sci Rep, 2018, 8: 10746. DOI: 10.1038/s41598-018-28792-1
    [51]
    Sies H, Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents[J]. Nat Rev Mol Cell Biol, 2020, 21: 363-383. DOI: 10.1038/s41580-020-0230-3
    [52]
    Arroyave-Ospina JC, Wu Z, Geng Y, et al. Role of Oxidative Stress in the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Implications for Prevention and Therapy[J]. Antioxidants (Basel), 2021, 10: 174. DOI: 10.3390/antiox10020174
    [53]
    Sun X, Seidman JS, Zhao P, et al. Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis[J]. Cell Metab, 2020, 31: 189-206. e8. DOI: 10.1016/j.cmet.2019.10.014
    [54]
    Shepard CR. TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism[J]. Front Endocrinol (Lausanne), 2020, 11: 613639.
    [55]
    Ding SZ, Minohara Y, Fan XJ, et al. Helicobacter pylori infection induces oxidative stress and programmed cell death in human gastric epithelial cells[J]. Infect Immun, 2007, 75: 4030-4039. DOI: 10.1128/IAI.00172-07
    [56]
    Handa O, Naito Y, Yoshikawa T. Helicobacter pylori: a ROS-inducing bacterial species in the stomach[J]. Inflamm Res, 2010, 59: 997-1003. DOI: 10.1007/s00011-010-0245-x
    [57]
    Oh JH, Lee JH, Cho MS, et al. Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease[J]. Nutrients, 2021, 13: 1013. DOI: 10.3390/nu13031013
    [58]
    Craven L, Rahman A, Nair Parvathy S, et al. Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial[J]. Am J Gastroenterol, 2020, 115: 1055-1065. DOI: 10.14309/ajg.0000000000000661
    [59]
    Aron-Wisnewsky J, Vigliotti C, Witjes J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders[J]. Nat Rev Gastroenterol Hepatol, 2020, 17: 279-297. DOI: 10.1038/s41575-020-0269-9
    [60]
    Heimesaat MM, Fischer A, Plickert R, et al. Helicobacter pylori induced gastric immunopathology is associated with distinct microbiota changes in the large intestines of long-term infected Mongolian gerbils[J]. PLoS One, 2014, 9: e100362. DOI: 10.1371/journal.pone.0100362
    [61]
    He C, Peng C, Xu X, et al. Probiotics mitigate Helico-bacter pylori-induced gastric inflammation and premalignant lesions in INS-GAS mice with the modulation of gastrointestinal microbiota[J]. Helicobacter, 2022, 27: e12898.
    [62]
    Cheng DD, He C, Ai HH, et al. The Possible Role of Helicobacter pylori Infection in Non-alcoholic Fatty Liver Disease[J]. Front Microbiol, 2017, 8: 743. DOI: 10.3389/fmicb.2017.00743
    [63]
    Doulberis M, Papaefthymiou A, Srivastava DS, et al. Update on the association between non-alcoholic fatty liver disease and Helicobacter pylori infection[J]. Int J Clin Pract, 2021, 75: e13737.
    [64]
    Zhang C, Guo L, Qin Y, et al. Correlation between Helicobacter pylori infection and polymorphism of adiponectin gene promoter-11391G/A, superoxide dismutase gene in nonalcoholic fatty liver disease[J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2016, 41: 359-366.
    [65]
    张超贤, 郭李柯, 张利利, 等. 幽门螺杆菌感染与PPARγ2基因Pro12Ala、GPx-1基因Pro198Leu多态性的交互作用和非酒精性脂肪性肝病的关系[J]. 临床肝胆病杂志, 2019, 35: 1551-1559. https://www.cnki.com.cn/Article/CJFDTOTAL-LCGD201907032.htm
    [66]
    方德周, 方彦旭, 贾星星. HP感染后Men1基因对非酒精性脂肪肝病及炎症反应的调控机制[J]. 基因组学与应用生物学, 2020, 39: 1824-1829. https://www.cnki.com.cn/Article/CJFDTOTAL-GXNB202004048.htm
    [67]
    Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73: 202-209. DOI: 10.1016/j.jhep.2020.03.039
    • Related Articles

  • Related Articles

    [1]LIU Miaomiao, YUE Hongmei, LI Yating, XU Jinhui, WU Xingdong, ZHU Haobin. Obstructive Sleep Apnea-induced Gut Dysbiosis and Ischaemic Stroke: Mechanism and Research Progress[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 382-386. DOI: 10.12290/xhyxzz.2023-0452
    [2]ZHANG Lu, LI Jian. Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 911-914. DOI: 10.12290/xhyxzz.2023-0227
    [3]ZHENG Meiling, FAN Qingli, ZHONG Lianmei. Intestinal Microbiota Polymorphism of Epilepsy Patients in Middle and High Altitude Areas: A Case-control Study[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 881-888. DOI: 10.12290/xhyxzz.2022-0533
    [4]LUO Xin, PANG Kun, CHEN Jianxiong, WANG Hongzhe, XU Xinjie, LI Bing, JIA Xinmiao, YOU Xin. Differences of Intestinal Flora in Children with Autism Spectrum Disorder with Different Levels of Serum Total 25-hydroxyvitamin D[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 812-820. DOI: 10.12290/xhyxzz.2022-0254
    [5]GAO Zhongshan, REN Ming, MA Yulan, ZHU Lulu. Polymorphism of Gut Microbiota in High Altitude Tibetan Patients with Coronary Artery Heart Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 332-340. DOI: 10.12290/xhyxzz.2021-0652
    [6]Ri-liga WU, Rong MU. Intestinal Microbiota in Systemic Sclerosis[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 263-267. DOI: 10.3969/j.issn.1674-9081.2019.03.013
    [7]Li-wei WANG, Zhi-min DUAN, Jian-bo TONG, Rong ZENG, Hao-xiang XU, Min LI. Diversity Analysis of Intestinal Microbiota in Psoriasis Patients: A Single-center Prospective Study[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 223-230. DOI: 10.3969/j.issn.1674-9081.2019.03.007
    [8]Ying-he LI, Xiang-chen MENG, Peng-guang YAN, Hong YANG, Ji LI, Jia-ming QIAN, Jing-nan LI. Relevance between Glucocorticoid Treatment and the Intestinal Microbiota of Patients with Moderately Severe Ulcerative Colitis: A Single-center Retrospective Study[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 216-222. DOI: 10.3969/j.issn.1674-9081.2019.03.006
    [9]Yu-hao JIAO, Feng-chun ZHANG. New Insights into Research on the Role of Gut Microbiota in Human Immune System[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 193-196. DOI: 10.3969/j.issn.1674-9081.2019.03.001

  • Cited by

    Periodical cited type(2)

    1. 侯昱丞，赵洪强，董草儿，吴广东，童翾，李昂，卢倩，陈虹，汤睿. 免疫检查点抑制剂相关胆管炎的研究进展. 临床肝胆病杂志. 2023(02): 463-468 .
    2. 苏春梅，李雅静，徐志华，王强，付金华. 恶性黑色素瘤应用PD-1抑制剂治疗中的免疫性肝损伤分析. 中国现代药物应用. 2022(18): 125-129 .

    Other cited types(1)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (304) PDF downloads (75) Cited by(3)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close